Recent Investment Analysts’ Ratings Updates for Caris Life Sciences (CAI)

A number of research firms have changed their ratings and price targets for Caris Life Sciences (NASDAQ: CAI):

• 5/11/2026 – Caris Life Sciences was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 5/8/2026 – Caris Life Sciences is now covered by New Street Research. They set a “market perform” rating on the stock.
• 5/8/2026 – Caris Life Sciences was given a new $22.00 price target by Robert W. Baird.
• 5/8/2026 – Caris Life Sciences had its price target lowered by Citigroup Inc. from $35.00 to $28.00. They now have a “buy” rating on the stock.
• 5/8/2026 – Caris Life Sciences had its price target lowered by JPMorgan Chase & Co. from $35.00 to $30.00. They now have an “overweight” rating on the stock.
• 5/8/2026 – Caris Life Sciences had its price target lowered by BTIG Research from $38.00 to $32.00. They now have a “buy” rating on the stock.
• 5/2/2026 – Caris Life Sciences was downgraded by Wall Street Zen from “buy” to “hold”.
• 4/13/2026 – Caris Life Sciences is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $28.00 price target on the stock.
• 4/10/2026 – Caris Life Sciences is now covered by Piper Sandler. They set a “neutral” rating and a $21.00 price target on the stock.
• 4/1/2026 – Caris Life Sciences is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $27.00 price target on the stock.

Insider Activity at Caris Life Sciences

In other Caris Life Sciences news, Director Jeff L. Vacirca purchased 31,050 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was acquired at an average cost of $16.15 per share, with a total value of $501,457.50. Following the acquisition, the director owned 49,671 shares of the company’s stock, valued at approximately $802,186.65. This represents a 166.75% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 7.80% of the company’s stock.

Get Caris Life Sciences Inc alerts:

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.

See Also

• Five stocks we like better than Caris Life Sciences
• Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
• As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
• Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
• The Silver Lining of Last Week’s Hims & Hers Earnings Miss

Receive News & Ratings for Caris Life Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caris Life Sciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.